Goal-Directed Cardiopulmonary Resuscitation in Cardiac Arrest Using a Novel Physiological Target: A Pilot Mechanistic Randomized Control Trial
The proposed study is a single-center, randomized controlled pilot trial of adults who suffer in-hospital cardiac arrests. Using cerebral oxygenation and end-tidal carbon dioxide physiological targets to predict survival and neurological outcome, the impact of physiological-feedback CPR will be assessed. 150 adult patients who have a cardiac arrest event at NYU Tisch Hospital will be randomized to one of two treatment groups: (1) Physiological-Feedback CPR or (2) Non-Physiological (Audiovisual) Feedback CPR.
GOG-3082 - Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination with Gemcitabine in Adult Subjects with Platinum-Resistant Ovarian Carcinoma Endometrial Adenocarcinoma and Urothelial Carcinoma Based on Acrivon OncoSignature Status
This is a clinical study to test a drug called ACR-368 (also known as Prexasertib) for the treatment of ovarian, endometrial, and urothelial cancer that has returned and is resistant to platinum-based chemotherapy. The study will test ACR-368 on its own and in combination with a low-dose chemotherapy drug called Gemcitabine. Patients will be selected for the study based on the results of a test called OncoSignature (a patient selection tumor biopsy test), which will predict how effective ACR-368 will be for each patient. Patients will be allocated to one of two groups based on their OncoSignature result: Arm 1 for patients with a positive OncoSignature result and Arm 2 for patients with a negative or inconclusive OncoSignature result. In Arm 1, patients with a positive OncoSignature result will receive ACR-368 alone in a Phase 2 study. In Arm 2, patients with a negative or inconclusive OncoSignature result will receive a combination of ACR-368 and low-dose gemcitabine in a Phase 1b study to determine the safe and recommended dose of the combination. A Phase 2 study will then test the combination for effectiveness and safety in each cancer type.
Golf Lab | NYU Langone Health
The Golf Lab at NYU Langone’s Sports Performance Center helps golfers improve their game and avoid injury.
Gout Treatment Center | NYU Langone Health
Experts at NYU Langone’s Gout Treatment Center care for people with gout and other crystal-induced arthritis.
Gout Treatment Center Doctors | NYU Langone Health
Find a doctor at the Gout Treatment Center at NYU Langone.
Government & Community Affairs at NYU Langone Health | NYU Langone Health
NYU Langone Health works with government and community organizations to create healthier communities in the New York metropolitan area.
Grace Y. Ko | NYU Langone Health
Grace Y. Ko, NYU Langone’s executive vice president for development and alumni affairs, is responsible for raising philanthropic support.
Graves’ Disease in Children | NYU Langone Health
Experts at Hassenfeld Children’s Hospital at NYU Langone treat children and adolescents with Graves’ disease, an autoimmune condition.
Group Psychotherapy | NYU Langone Health
Specialists at NYU Langone Psychiatry Associates offer group psychotherapy to help facilitate personal growth and healing.
Growth Plate Injuries in Children | NYU Langone Health
Doctors at Hassenfeld Children’s Hospital at NYU Langone diagnose and treat growth plate injuries in children and adolescents.